All-Time High’s, Successful IPO’s, & Bullish Indicators Were Served Again This Week

By John F. Heerdink, Jr.

It’s a long weekend for many of us, as we are celebrating Valentine’s Day, the Chinese New Year, & then on Monday we are observing President’s Day while the market is closed. I hope that you made a fortune in the markets again this week as it was up to its record setting ways. Investors once again consumed a number of headlines and statements that generally extended a bullish stance. Investors received multiple confirmations that the distribution of the COVID-19 vaccines were pushing forward, while President Joe Biden stated that 230 million Americans would receive a vaccination by the end of July. Fed Chair Jerome Powell also stated that the Fed will be keeping interest rates near zero until the Fed sees maximum employment & the economy achieves a targeted +2% sustainable inflation rate. He also confirmed the Fed will continue purchasing a minimum of $120B of bonds every month to add support. In addition, newly appointed Treasury Secretary Janet Yellen shared that the US could return to full employment in 2022 if President Biden’s $1.9T stimulus package is put in to place. Yellen further confirmed on her interview on CNN’s “State of the Union, “There’s absolutely no reason why we should suffer through a long slow recovery. I would expect that if this package is passed that we would get back to full employment next year.” To cement our understanding regarding her position, she offered the following facts and/or understanding: 1) Long-term unemployment is nearing a historical peak almost a year after the pandemic began, nearly 9M fewer Americans are working now than last February, Democrats in Congress have moved to pass stimulus without GOP support, & the unemployment rate will remain elevated for years to come without more federal support, according to a federal report. The markets also saw a number of generally positive corporate earnings reports and outlooks that left many with a bullish take.

The indices again all reached record high this week & ended as follows: The S&P 500 closed at 3,934.83 (+1.% wk/wk) (+4.8 YTD), the Dow ended at 31,458.40 (+1% wk/wk) (+2.8 YTD), & the Nasdaq Composite closed at 14,095.47 (+1.7% wk/wk ) (+9.4 YTD) while the Russell 2000 enjoyed the best move of the week closing at 2,289.36 (+2.5% wk/wk) (+15.9 YTD).

Eight of 11 sectors ended in the green this week with the energy sector leading the the pack again jumping another 4.3% after as oil prices rose to $59.47/bbl up nearly $3/bbl week over week. The sectors that ended lower were the utilities sector down 1.8%, the consumer discretionary sector down 1.3%, & the consumer staples sector down .1%.

THE “MACRO”

The macroeconomic schedule also produced a number of reports as follows this week that showed improvement in many cases but also firmly confirmed the case for the stimulus package to be put into place. On Tuesday, the job openings report showed a rise 6.646M in December. The NFIB Small Business Optimism Index report confirmed a drop to 95. Tomorrow’s schedule will produce the Consumer Price Index report for January, the Treasury Budget report for January, the Wholesale Inventories report for December, & the MBA Mortgage Applications Index report. On Wednesday, we received the Total CPI report for January which rose by .3% month/month while the Core CPI (excludes food & energy) was even. The Wholesale inventories report confirmed a rise by .3 month/month in December. The weekly MBA Mortgage Applications Index report confirmed a drop by 4.1%. Tomorrow’s schedule will produce the the weekly Initial and Continuing Claims report. On Thursday, the schedule delivered the Initial claims report which confirmed a drop by 19k to 793k while Continuing claims for the week ending January 30 dropped by 145k to 4.545M. On Friday, the preliminary February reading of the University of Michigan Index of Consumer Sentiment report confined a drop to 76.2.

Next week, we will receive the February preliminary Markit Purchasing Managers’ Index report, the producer inflation report, & the retail sales growth report.

IPO’s

There were a number IPO’s this week as the market machine was working. Austin-based dating-app operator, Bumble, Inc,(BMBL), debuted its IPO on the Nasdaq this week seeing its shares close at $70.31, +63.51% on Thursday before legging up to $75.46 on Friday. BMBL’s IPO priced 50,000,000 shares of its Class A common stock at a price to the public of $43.00 per share. Bumble has granted the underwriters a 30-day option to purchase up to an additional 7,500,000 shares of Class A common stock. Goldman Sachs & Co. LLC and Citigroup are acting as joint lead book-running managers and as representatives of the underwriters for the offering. CEO Whitney Wolfe Herd, who created the company in 2014, is now worth more than $1b at the age of 31 and is the youngest woman to lead a company to IPO. Connecticut-based health care payment program company, Signify Health Inc. (SGFY) also priced its IPO raising $564 million. The Company sold 23.5 million shares in the IPO priced at $24 share. SGFY shares closed at $36.40, +15.34% on Friday.

TECH HIGHLIGHTS

Shares of Microsoft (MSFT) closed at $244.99/share, +.2% Friday & up slightly from last Friday’s close of $$242.20/share after reporting better than expected earnings recently. Intel (INTC) closed at $61.81, +1.9% Friday, moving up from last Friday’s $58.18/share. Bob Swan, Intel’s outgoing CEO, bought more than $1.5M of Intel’s stock after they reported on Jan. 22.

Salesforce (CRM) closed at $240.37, -.36% on Friday up slightly from last Friday’s close of $238.89. Salesforce announced this week that in connection with the Company’s previously announced solicitation of consents on behalf of Slack Technologies, Inc. acqusition, that they had receipt of requisite consents, effective time and expiration date of consent solicitation.

NVIDIA Corporation (NVDA) achieved a new all-time high of $611.61 this week prior to closing at $598.45 on Friday amid the “global chip shortage” as their chips power the future of self-driving cars and cloud gaming.

Peter Thiel co-founded software firm Palantir Technologies (PLTR) closed at $31.91/share, -3.62% Friday & down from the $34.05/share close last week. This week, PLTR announced a new partnership consisting of IBM’s hybrid cloud data platform designed to deliver AI for business, with Palantir’s next generation operations platform for building applications.

Leading EV car maker Tesla (TSLA) closed at $816.12, +.55% Friday, but down from the $852.23 close last Friday as it confirmed that it had invested $1.5B into Bitcoin. Chinese EV concern NIO Limited (NIO) closed at $59.85, -.7% on Friday, but up from $56.67/share last Friday.

The ever so popular FAANG’s ended as follows: Apple (AAPL) shares closed at $135.37 down last Friday’s close of $136.76, Amazon (AMZN) closed at $3,277.71 down from last Friday’s close of $3,352.15, Alphabet (GOOG) closed at $2,104.11 up strongly from last Friday’s close of $2,098, Facebook (FB) closed at $270.50 up from last Friday’s close of $268.10 & Netflix (NFLX) closed at $556.52 up from last Friday’s close of $550.79/share.

ACROSS THE DOW 30

Johnson & Johnson (JNJ) closed at $166.58/share, +.31% Friday & up from last week’s close of $164.45 as its CEO stated that COVID-19 boosters may be needed. Pharmaceutical giant Merck (MRK) closed at $75/share, +.35% Friday and down again from last Friday’s close of $75.80/share.

Shares of Coca-Cola (KO) closed at $50.69/share bumping up again from last Friday’s close of $49.65/share after hiking its dividend and stating that they see a strong recovery after virus hit their better than expected Q4 earnings. Shares of Disney (DIS) closed at $187.67/share, -1.7% on Friday, but up sharply from last Friday’s at $181.16/share. The Walt Disney Company (DIS) reported its fiscal first-quarter earnings, riding high on its streaming services. Disney+ subscribers jumped to 94.9 million as of Jan. 2, an increase of 9% from 86.8 million on Dec. 2 and 258% from a year ago. Shares of Nike (NKE) closed at $142.12/share down from last Friday’s close at $145.11/share. Nike will pay a quarterly cash dividend of $.275 per share to all outstanding common stock shareholders of Class A & Class B as of March 1, 2021. The dividend is to be paid on April 1, 2021. Walmart (WMT) closed at $144.47/share slightly up from last Friday’s close of $144.36/share.

Shares of Deere (DE) closed at $313/share, -.46% Friday, but up again from last week’s Friday close of $309.24/share. Caterpillar (CAT) closed at $197.99/share, -.18% & up again from last Friday’s close of $193/share. Caterpillar recently beat Q4 estimates and see a housing boom leading the 2021 sales recovery.

Boeing (BA) closed $210.98, +.15% on Friday & up from last Friday’s close of $207.93/share. Morgan Stanley recently upgraded Boeing as a ‘COVID-19 recovery play.

BIOTECH

iShares Nasdaq Biotechnology ETF (IBB) closed at $170.72 up from last week’s close of $169.05. The NYSE ARCA Biotech Index (^BTK) closed at 6,232.70 down from last week’s close of 6,237.92.

FINANCIALS

Around the sector, Goldman Sachs (GS) closed trading at $306.32/share, +1.32% Friday & up from last Friday’s close of $293.50/share, American Express (AXP) closed at $129.62/share, +1.02% on Friday & up ~$3 from the $126.28/share close last Friday, Visa (V) closed trading at $209.96/share, -.33% Friday but up from the $208.77/share close last Friday & shares of Morgan Stanley (MS) closed at $74.61/share, +1.21% Friday, but down from last Friday’s close of $83.22/share. JPMorgan Chase (JPM) closed at $141.25, +1.42% Friday & up from the $137.98/share close last Friday & Citigroup (C) $63.63/share up from the close of $62.58/share last week. PayPal Holdings (PYPL) closed at $298.37/share up significantly again from last Friday’s close of $269.44/share after recently beating Q4 expectations and Square (SQ) closed at $272.75 up significantly again from last week’s close of $240.38/share after it was reported that they were picking up Cash App users amid the “Robinhood drama”.

Reportedly, MasterCard (MA) & the Bank of New York Mellon (BK) are seeking to incorporate cryptocurrencies into their respective businesses.

GOLD & SILVER MARKETS

Gold prices closed at $1826 up from the $1,816/oz. close last week. This Friday silver prices closed at $27.43/oz. slightly up from the $27.01/oz. close last Friday. Barrick Gold Corp. (GOLD) closed trading at $22.15 down slightly from last Friday’s close of $22.33/share. North American silver and gold producer Hecla Mining Company (HL) ended the week at $6.17/share slightly up from last Friday’s close of $6.12/share. Phillips S. Baker, Jr., President, and CEO of Hecla Mining Company (NYSE: HL), discussed “The Silver Squeeze” while addressing questions from the Tribe Public where he offered valuable insights on silver prices throughout history and the recent volatility that helped move silver related stocks & silver prices. Please view the event video now.

MONEY UPDATE

The U.S. Dollar Index strengthened to end the week at 90.45 marginally down from 90.99 last Friday. The 2-yr Treasury yield closed higher at .10% compared to the prior week at .09%, the 10-yr yield closed up 3 basis points ending at 1.2% while the 30-yr yield ended at 2.01% ticking up from 1.97% last Friday.

TRADING NEXT WEEK

Only 4 trading sessions next week as the stock market will be closed on Monday, February 15 to observe President’s Day in the good ‘ole US of A.

VP WATCHLIST UPDATES

Shares of Chinook Therapeutics (KDNY), a clinical-stage biotechnology company developing precision medicines for kidney diseases, closed at $14.84 down from the $16.15 close last week. Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases, a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

- Last week, Chinook announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for CHK-336, an investigational oral small molecule inhibitor of lactate dehydrogenase A (LDHA) for primary hyperoxaluria (PH). PH is a group (PH1, PH2 and PH3) of ultra-rare genetic diseases caused by enzyme mutations that result in excess oxalate production in the liver, and in its most severe forms, can lead to end-stage kidney disease at a young age. Inhibition of LDHA with CHK-336 allows for the potential to treat all forms of PH and other disorders arising from excess oxalate, while its liver-targeted tissue distribution profile enables maximal inhibition of liver oxalate production with minimal systemic exposure. Please read the story here.

- I hosted Chinook’s President & CEO Eric Dobmeier at our sister organization Tribe Public’s Presentation and Q&A event, Tuesday, Jan. 26th which you can watch now at Tribe Public YouTube Channel. Mr. Dobmeier previously was the President and CEO of Silverback Therapeutics, a Seattle-based biotechnology company in the immuno-oncology space. Prior to that, he spent more than 15 years at Seattle Genetics, most recently as Chief Operating Officer, where he oversaw business development, corporate communications, manufacturing, program/alliance management activities and corporate strategy initiatives. While at Seattle Genetics, Eric was also directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Earlier in his career, he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric has a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Atara Biotherapeutics and Adaptive Biotechnologies.

- Chinook has well-funded development programs with participation in a $115 million private placement financing concurrent with the close of a merger with Aduro Biotech in Q4 2020 from top-tier healthcare investors including, EcoR1 Capital, OrbiMed Advisors, funds managed by Rock Springs Capital, Fidelity Management and Research Company LLC, Avidity Partners, Surveyor Capital (a Citadel company), Ally Bridge Group, Monashee Investment Management LLC, Northleaf Capital Partners, Janus Henderson Investors, Sphera Biotech and others.

Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $102.45/share down from $105.19 last Friday still shy of its recently achieved a new all-time high of $121.16. Recently, FATE announced the pricing of an underwritten public offering of ~$432 million at $85.50. Jefferies, BofA Securities, SVB Leerink and Barclays acted as joint book-running managers for the offering. We started with this one folks over 3 years ago when it was in the $3 range.

- Fate is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders.

- Recently, Fate presented a patient case study from the Company’s Phase 1 clinical trial of FT596, its universal, off-the-shelf, CD19-targeted chimeric antigen receptor (CAR) natural killer (NK) cell product candidate, at the 62nd Annual Society of Hematology Annual Meeting and Exposition and the street loved it. NK cells are the body’s first line of defense against viral infections and cancerous cells with an innate ability to rapidly seek and destroy transformed cells. NK cell therapy has the potential to 1) target multiple pathogenic antigens with measurably more efficient cytotoxicity, 2) be better controlled to reduce risk of cytokine storms and 3) be produced from a variety of sources without relying on patient-specific immune cells. Dr. Wayne Chu, Senior Vice President, Clinical Development of Fate Therapeutics stated, “The safety, pharmacokinetics and clinical activity observed following both the first and second single-dose treatment cycles of FT596 are compelling, especially when considering that the administered cell dose was significantly lower than the recommended cell dose of FDA-approved autologous CD19-targeted CAR T-cell therapies and that the heavily pre-treated patient was refractory to last prior therapy. We are excited the CAR component of FT596 has shown clinical activity at this low dose level, and we continue to enroll patients in dose escalation with FT596 as a monotherapy and in combination with rituximab. Our recent Phase 1 clinical data with FT516 in combination with rituximab, which demonstrate the potential of our novel hnCD16 Fc receptor to potentiate ADCC and drive complete responses, support our belief that the multi-antigen targeting functionality of FT596 may offer best-in-class potential for patients with B-cell malignancies.”

- We have made another investment in a private company called Cytovia Therapeutics that owns its own NK cell platform that some investors are calling “FATE 2.0”. They are seeking to go next year in Q2/Q3 as there is room in the markets for another NK cell company. Their website is www.cytoviatx.com .

Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, closed at $3.64/share up +14.11% with an average trading volume of 20.48M shares/day and a $260.53M MKT Cap. This move came after Atossa recently announced updated findings following 26 months of Expanded Access (or “compassionate use”) single-patient studies of Atossa’s Endoxifen. “To date, the patient has not had a recurrence of breast cancer, as assessed by clinical breast examination and mammography; has not had treatment-related changes in periodic laboratory blood tests and general clinical examinations; and, the treatment has been well tolerated, including an absence of typical vasomotor symptoms commonly associated with tamoxifen (for example, night sweats and hot flashes), an FDA-approved drug frequently prescribed for breast cancer treatment,” commented Sidney Goldblatt, M.D., Principal Investigator. “This patient, like many breast cancer patients, was reluctant to take tamoxifen because of the well-documented side effects associated with that drug and because she lacked the proper liver enzymes to properly metabolize tamoxifen. We are very encouraged by this patient’s experience with our Endoxifen over the past two years. Her experience serves as a model for ongoing development efforts,” commented Steve Quay, Ph.D., M.D., Atossa’s President and CEO.

- Recently, I hosted Tribe Public’s Webinar Presentation and Q&A Event with Steven Quay, MD, PhD, CEO & Founder & Kyle Guse CFO of Atossa Therapeutics (NASDAQ: ATOS) who delivered a presentation titled “The Important Role of COVID-19 Therapeutics In A Post-Vaccine World.” They also addressed Q&A session at the end of the presentation. Please view it here.

- Atossa recently announced blinded preliminary results from its Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. AT-301 was found to be safe and well tolerated in this study at two different dose levels in both single and multiple dose forms over 14 days. AT-301 is being developed for at home use for patients recently diagnosed with COVID-19. There are currently no FDA-approved therapies to treat COVID-19 at home. Learn more now.

- Atossa announced that it has received $21 million from the exercise of outstanding warrants. The warrants were issued in financings in December 2020 and January 2021. Kyle Guse, CFO and General Counsel stated, “In the past 60 days, we have made great progress in adding substantial cash resources so that we can accelerate development of our COVID-19 and breast cancer therapies. We completed financings with gross proceeds of approximately $60 million and in the past week have added an additional $21 million to our balance sheet through the exercise of outstanding warrants. We look forward to the speed at which we can now advance our programs in 2021.”

- Atossa is seeking in the near term to get an FDA nod to move into a Phase 2 trial with its nasal spray COVID-19 therapy.

Shares of INVO Bioscience (NASDAQ: INVO) closed at $4.18/share up from $2.80 close last Friday. INVO has closed soundly above its 50-day moving average of $3.10. There appears to be a significant gap up to its $5.06 or 200-day moving average when you look at the charts.

- Recently, INVO announced it has advanced its commercialization efforts into the European fertility market by securing initial orders of INVOcell in Madrid and Barcelona, Spain. INVOcell will initially be available at three separate existing fertility clinics which have placed orders and commenced training. Please read the story here.

- INVO Bioscience, Inc. (INVO) is a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System. Industry forecasts suggest that only 1% to 2% of the estimated 150 million infertile couples worldwide are currently being treated. INVO’s mission is to increase access to care and expand infertility treatment across the globe with a goal of improving patient affordability and industry capacity. Since January 2019, INVO Bioscience has signed commercialization agreements in the United States, India, as well as parts of Africa and Eurasia and Mexico for the INVOcell device.

- INVO’s Management Issued a letter to shareholders recently that spoke to their key developments and future initiatives that have positioned their product INVOcell® within the severely underserved fertility market. PLEASE READ IT HERE.

- INVO received BUY Ratings from both Roth Capital ($5 PT) & Collier International Securities ( $5.75 PT) in December, 2020.

- Recently, INVO filed an 8k highlighting three new partners that they have established to distribute or develop invocell only clinics in Malaysia and North Macedonia.

- INVO recently announced that it has entered an exclusive distribution agreement with Galaxy Pharma Ltd. to distribute the INVOcell system within Pakistan, the fifth most populous country in the world with approximately 212 million people. Galaxy Pharma is a leader in providing products and services to the country’s current full-service In Vitro Fertilization (IVF) facilities, and has joint ventures operating an additional 21 facilities focused on administering Intrauterine Insemination (IUI) via OBGYN’s.

Shares of NeuBase Therapeutics (NBSE) closed trading this week at $11.69 up from $10.79/share last week after establishing a new all time high of $12.89. This week, Neubase reported its financial results for the three-month period ended December 31, 2020. Review the story here.

- Oppenheimer’s analyst Hartaj Singh reiterated his OUTPERFORM Rating and his Price Target of $17 this week.

- Last week, NBSE announced the execution of a binding agreement to acquire infrastructure, programs and intellectual property for several peptide-nucleic acid (PNA) scaffolds from Vera Therapeutics, formerly known as TruCode Gene Repair, Inc. The technology has demonstrated the ability to resolve disease in genetic models of several human indications. The acquisition was reported to bolster NeuBase’s capabilities and reinforces the Company’s position as a leader in the field of genetic medicine. Read the complete story.

- The company expects to successfully negotiate a corporate licensing deal of some kind prior to the one-year anniversary of their April, 2020 equity financing as stated in a recent interview.

- NeuBase is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities for the hundreds of millions of people affected by rare genetic diseases, including those that can only be treated through accessing of secondary RNA structures. Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

- Recently, NeuBase announced positive in vitro and in vivo preclinical data for its PATrOL™-enabled anti-gene therapies for the treatment of myotonic dystrophy type 1 (DM1). These new data show that PATrOL-enabled Compound A can rapidly resolve mis-splicing without negatively impacting DMPK protein levels. They also support the potential of NeuBase’s anti-gene approach to comprehensively treat the underlying cause of DM1. Curt Bradshaw, Ph.D., Chief Scientific Officer of NeuBase stated “Despite the fact that the genetic basis of DM1 is well understood today, there is still an urgent need to find the first genetically-targeted, disease-modifying treatment option for affected patients. DM1 is caused by a genetic mutation in the DMPK gene leading to mis-splicing of a broad spectrum of genes and DMPK protein insufficiency. A treatment option that addresses mis-splicing while retaining functional DMPK protein levels may be key to treating all aspects of DM1.”
- Recently, I hosted a FREE Presentation & Q&A Event for our sister organization Tribe Public with the CEO & Founder of NeuBase, Dietrich Stephan, Ph.D., an industry veteran who is considered one of the fathers of the field of precision medicine. The presentation is titled “Accelerating the Genetic Revolution with a New Class of Synthetic Medicines.” You can view the recording at the Tribe Public Channel.

Clean hydrogen solution provider Plug Power (PLUG) closed at $63.19/share up from $65.77 last Friday. This week, PLUG announced the completion of its previously announced upsized offering of 32,200,000 shares, which includes the underwriters option to purchase an additional 4,200,000 of its common stock. The shares were sold at a price to the public of $65 per share with net proceeds in excess of $2B. This transaction signifies the largest bought deal in the cleantech sector. This offering represents the third largest follow-on primary block trade with Morgan Stanley as a sole bookrunner in any market sector historically. Proceeds from this transaction, and final closing of the partnership with SK Group, will bring the total cash balance to over $5B. This liquidity positions Plug Power to execute and accelerate it’s green hydrogen and overall growth strategy.

- It has been a nice ride from the Fall 2020 in the $10.50 range when we identified it. With the significantly bolstered balance sheet, the Biden push for clean energy alternatives and a number of new corporate relationships & initiatives this company continues to impress.

- Recently, PLUG announced that they are jointly developing hydrogen-powered light commercial vehicles (LCV) with French carmaker Renault.

- Plug and the SK Group also recently announced that the companies intend to form a strategic partnership to accelerate hydrogen as an alternative energy source in Asian markets. SK Group will make a $1.5 billion (9.9% stake) strategic investment in Plug Power.

- Recently, PLUG announced that is expanding is relationship with Walmart (WMT).

Please review our complete VP Watchlist now that includes nine highlighted companies. The pages will allow you to learn more and keep up with these companies daily.

QUOTE OF WEEK

“It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros

Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward.

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates.

Investing & Inspiration

“It’s not whether you’re right or wrong that’s important, but how much money you make when you’re right and how much you lose when you’re wrong.” – George Soros
“In investing, what is comfortable is rarely profitable.” — Robert Arnott
“Don’t look for the needle in the haystack. Just buy the haystack!” — John Bogle
“No Price is too low for a bear or too high for a bull.” — Anonymous
“Investment is an asset or item that is purchased with the hope that it will generate income or appreciate in the future.” — Anonymous
“Behind every stock is a company. Find out what it’s doing.” — Peter Lynch
“Wise spending is part of wise investing. And it’s never too late to start.” –Rhonda Katz
“If there is one common theme to the vast range of the world’s financial crises, it is that excessive debt accumulation, whether by the government, banks, corporations, or consumers, often poses greater systemic risks than it seems during a boom.” — Carmen Reinhart
“It amazes me how people are often more willing to act based on little or no data than to use data that is a challenge to assemble.” ― Robert Shiller
“A bull market is like sex. It feels best just before it ends.” — Barton Biggs
“The investor’s chief problem — even his worst enemy — is likely to be himself.” — Benjamin Graham
“No profession requires more hard work, intelligence, patience, and mental discipline than successful speculation.” – Robert Rhea
“The most contrarian thing of all is not to oppose the crowd but to think for yourself.” — Peter Thiel
“Money is like a sixth sense – and you can’t make use of the other five without it.” – William Somerset Maugham
“Compound interest is the eighth wonder of the world. He who understands it, earns it. He who doesn’t, pays it.” — Albert Einstein
“The stock market is a device for transferring money from the impatient to the patient.” – Warren Buffett
“Thousands of experts study overbought indicators, head-and-shoulder patterns, put-call ratios, the Fed’s policy on money supply…and they can’t predict markets with any useful consistency, any more than the gizzard squeezers could tell the Roman emperors when the Huns would attack.” – Peter Lynch
“Investing puts money to work. The only reason to save money is to invest it.” – Grant Cardone
“Formal education will make you a living; self-education will make you a fortune.” – Jim Rohn
“You cannot save time for your future use however you can invest time for your future.” – John F. Heerdink, Jr.
“We always live in an uncertain world. What is certain is that the United States will go forward over time.” – Warren Buffett
“Never test the depth of the river with both of your feet.” – Warren Buffet
“Know what you own, and know why you own it.” – Peter Lynch
“Liquidity is only there when you don’t need it.” -Old Proverb
“There is no such thing as no risk. There’s only this choice of what to risk, and when to risk it.” – Nick Murray
“If you want to be a millionaire, start with a billion dollars and launch a new airline.” – Richard Branson
“Fear incites human action far more urgently than does the impressive weight of historical evidence.” – Jeremy Siegel
“In investing, what is comfortable is rarely profitable.” – Robert Arnott
“Spend each day trying to be a little wiser than you were when you woke up.” – Charlie Munger
“The entrance strategy is actually more important than the exit strategy.” – Edward Lampert
“The rivers don’t drink their own water; Trees don’t eat their own fruits. The sun does not shine for itself, And flowers do not spread their fragrance For themselves. Living for others is a rule of nature” – PopeFrancis
“It is impossible to produce superior performance unless you do something different from the majority.” – John Templeton
“Inaction and patience are almost always the wisest options for investors in the stock market.” – Guy Spier
“Remember that the stock market is a manic depressive.” – Warren Buffett
“An investment in knowledge pays the best interest.” – Benjamin Franklin
“I believe the returns on investment in the poor are just as exciting as successes achieved in the business arena, and they are even more meaningful!” -Bill Gates
“Every portfolio benefits from bonds; they provide a cushion when the stock market hits a rough patch. But avoiding stocks completely could mean your investment won’t grow any faster than the rate of inflation.” – Suze Orman
“The tax on capital gains directly affects investment decisions, the mobility and flow of risk capital… the ease or difficulty experienced by new ventures in obtaining capital, and thereby the strength and potential for growth in the economy.” – John F. Kennedy
“If all the economists were laid end to end, they’d never reach a conclusion.
-George Bernard Shaw
“The riskiest thing we can do is just maintain the status quo. I get up at 4:30 in the morning, seven days a week, no matter where I am in the world. I think it is important for people who are given leadership roles to assume that role immediately. What I’ve really learned over time is that optimism is a very, very important part of leadership.” – Bob Iger, Former Ceo of Disney
“In the short run, the market is a voting machine. But in the long run, it is a weighing machine.” – Ben Graham
“In investing, what is comfortable is rarely profitable.” -Robert Arnott
“The fundamental law of investing is the uncertainty of the future.” -Peter Bernstein
“How many millionaires do you know who have become wealthy by investing in savings accounts?” -Robert G Allen
“Greed is all right, by the way. I think greed is healthy. You can be greedy and still feel good about yourself.”-Ivan Boesky
“Michael Marcus taught me one other thing that is absolutely critical: You have to be willing to make mistakes regularly; there is nothing wrong with it. Michael taught me about making your best judgment, being wrong, making your next best judgment, being wrong, making your third best judgment, and then doubling your money.” -Bruce Kovner
“The policy of being too cautious is the greatest risk of all.” -Jawaharlal Nehru
“I talk about macro themes a lot because they are fun to talk about, but it is the risk management that is the most important thing. The risk control is all bottom-up. I structured the business right from the get-go so that we would have lots of diversification.” -Michael Platt
“Blaming speculators as a response to financial crisis goes back at least to the Greeks. It’s almost always the wrong response.” -Larry Summers